A detailed history of Efg Asset Management (North America) Corp. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 119,503 shares of RNA stock, worth $3.86 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
119,503
Previous 61,305 94.93%
Holding current value
$3.86 Million
Previous $2.82 Million 23.45%
% of portfolio
0.49%
Previous 0.48%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$29.08 - $52.5 $1.69 Million - $3.06 Million
58,198 Added 94.93%
119,503 $3.48 Million
Q3 2024

Nov 12, 2024

BUY
$37.21 - $48.14 $1.17 Million - $1.51 Million
31,313 Added 104.4%
61,305 $2.82 Million
Q2 2024

Jul 25, 2024

BUY
$22.73 - $40.85 $681,718 - $1.23 Million
29,992 New
29,992 $1.23 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.68B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.